OpenAI is enhancing its strategy to mitigate risks from artificial intelligence (AI) by investing in Red Queen Bio, a biotech startup focused on preventing the misuse of AI for biohazard creation. The company has led a $15 million seed round for Red Queen Bio, which emerged from the mRNA therapeutics firm Helix Nano. With AI’s potential to accelerate both drug development and the creation of dangerous biological agents, there’s an urgent need for defensive measures. Red Queen Bio aims to couple AI models with lab experiments to uncover vulnerabilities in biological systems and devise effective countermeasures. OpenAI is committed to supporting early-stage companies addressing AI-related safety issues, establishing a resilient biosecurity ecosystem. The investment, approved by unconflicted board members, emphasizes OpenAI’s pivotal role in advancing biosecurity amidst the growing threat of bioweapons linked to AI advancements.
Source link
